{
    "id": 32732,
    "fullName": "EGFR del exon26",
    "impact": "deletion",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "EGFR del exon26 is an EGFR splice variant caused by a mutation resulting in the deletion of exon 26 (PMID: 25826094). Del exon26 results in phosphorylation of Egfr, Stat3, and Akt to similar levels or wild-type protein, and is not transforming in one cell line, but results in constitutive phosphorylation of Egfr, Shc, and Akt in another cell line (PMID: 25826094), and therefore, its effect on Egfr protein function is unknown.",
            "references": [
                {
                    "id": 18089,
                    "pubMedId": 25826094,
                    "title": "Constitutive asymmetric dimerization drives oncogenic activation of epidermal growth factor receptor carboxyl-terminal deletion mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25826094"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 1956,
        "geneSymbol": "EGFR",
        "terms": [
            "EGFR",
            "ERBB",
            "ERBB1",
            "HER1",
            "mENA",
            "NISBD2",
            "PIG61"
        ]
    },
    "variant": "del exon26",
    "createDate": "03/10/2020",
    "updateDate": "03/10/2020",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 20836,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Gilotrif (afatinib) inhibited viability of transformed cells expressing EGFR del exon26 in culture (PMID: 25826094).",
            "molecularProfile": {
                "id": 35362,
                "profileName": "EGFR del exon26"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18089,
                    "pubMedId": 25826094,
                    "title": "Constitutive asymmetric dimerization drives oncogenic activation of epidermal growth factor receptor carboxyl-terminal deletion mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25826094"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20833,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Erbitux (cetuximab) inhibited viability of transformed cells expressing EGFR del exon26 in culture (PMID: 25826094).",
            "molecularProfile": {
                "id": 35362,
                "profileName": "EGFR del exon26"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18089,
                    "pubMedId": 25826094,
                    "title": "Constitutive asymmetric dimerization drives oncogenic activation of epidermal growth factor receptor carboxyl-terminal deletion mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25826094"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20834,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tarceva (erlotinib) inhibited viability of transformed cells expressing EGFR del exon26 in culture (PMID: 25826094).",
            "molecularProfile": {
                "id": 35362,
                "profileName": "EGFR del exon26"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18089,
                    "pubMedId": 25826094,
                    "title": "Constitutive asymmetric dimerization drives oncogenic activation of epidermal growth factor receptor carboxyl-terminal deletion mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25826094"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20835,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Vizimpro (dacomitinib) inhibited viability of transformed cells expressing EGFR del exon26 in culture (PMID: 25826094).",
            "molecularProfile": {
                "id": 35362,
                "profileName": "EGFR del exon26"
            },
            "therapy": {
                "id": 714,
                "therapyName": "Dacomitinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18089,
                    "pubMedId": 25826094,
                    "title": "Constitutive asymmetric dimerization drives oncogenic activation of epidermal growth factor receptor carboxyl-terminal deletion mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25826094"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 35362,
            "profileName": "EGFR del exon26",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}